Introduction
============

Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis, with cardiac involvement that commonly includes pericarditis, ischemia, and myocarditis ([@B1]). The early diagnosis of cardiovascular events and treatment are necessary because a delayed diagnosis may be associated with a worse prognosis. We herein report the case of a patient who presented to our hospital with worsening dyspnea, chest oppression, and numbness gradually spreading from the sole of the foot, who was diagnosed with EGPA complicated by Löffler endocarditis．

Case Report
===========

A 40-year-old man with a history of bronchial asthma, which had been diagnosed 10 years previously, was admitted to another hospital because of chest oppression and numbness gradually spreading from the sole of the foot. On admission, a laboratory analysis showed a white blood cell count of 30,500/mL with hypereosinophilia of 21,655/mL (71% of all white blood cells) and an elevated troponin T level (2.62 μg/L). Chest X-ray and whole-body computed tomography (CT) showed bilateral pneumonia, pleural effusion ([Fig. 1A and B](#g001){ref-type="fig"}), and paranasal sinusitis. Electrocardiography (ECG) showed an abnormal Q wave in V1-4 and horizontal ST depression in II III aVf V5-6. In addition, ultrasound cardiography (UCG) showed diffuse left ventricular (LV) hypokinesis and pericardial effusion. Emergent coronary angiography showed no substantial signs of coronary artery disease or arterial occlusion．

The patient was transferred to our hospital due to fever, weight loss, and a worsening respiratory status. He was diagnosed with eosinophilic pneumonia, and steroid therapy was initiated with oral prednisolone (50 mg/day) after steroid pulse treatment with intravenous methylprednisolone (1,000 mg/day) for three days. Although anti-myeloperoxidase antineutrophil cytoplasm antibodies were not detected, his systemic symptoms and laboratory findings met the diagnostic criteria for EGPA. Intermittent intravenous cyclophosphamide pulse therapy (750 mg/day, every four weeks) was added to the steroid treatment. Heparin, as anticoagulation therapy, was initiated due to the possibility of complication with eosinophilic cardiomyopathy．

![(A) Chest X-ray showed bilateral pneumonia. (B) Whole-body CT revealed bilateral pneumonia and pleural effusion.](1349-7235-58-0239-g001){#g001}

![Cine imaging. (A) End-diastolic two-chamber view at the onset of treatment. (B) End-systolic two-chamber view at the onset of treatment. (C) End-diastolic four-chamber view at the onset of treatment. (D) End-systolic four-chamber view at the onset of treatment. (E) End-diastolic two-chamber view after 3 months of treatment. (F) End-systolic two-chamber view after 3 months of treatment. (G) End-diastolic four-chamber view after 3 months of treatment. (H) End-systolic four-chamber view after 3 months of treatment.](1349-7235-58-0239-g002){#g002}

Cine imaging using the steady-state free precession technique demonstrated a decreased LV ejection fraction (28.0%) with diffuse severe LV hypokinesis and pericardial effusion ([Fig. 2A-D](#g002){ref-type="fig"}), which was in line with the UCG findings. Cardiac magnetic resonance (CMR) imaging with gadolinium contrast showed extensive subendocardial late gadolinium enhancement (LGE) in the left ventricle, indicating the presence of inflammatory edema and fibrosis ([Fig. 3A, B](#g003){ref-type="fig"}). The imaging characteristics of the partial myocardium on turbo spin-echo (TSE) T2-weighted imaging were compatible with Löffler endocarditis ([Fig. 4A, B](#g004){ref-type="fig"}). Anticoagulation with warfarin was concurrently started to prevent stroke. Brain MRI performed before the patient left our hospital revealed no cerebral infarcts. Treatment with oral prednisolone was tapered to a maintenance dose of 5 mg/day at our hospital during outpatient treatment. The patient also received intravenous cyclophosphamide pulse treatment each month as immunosuppressant therapy．

![Endocardial late gadolinium enhancement (LGE) indicating the presence of inflammatory edema and fibrosis. (A) Four-chamber view at the onset of treatment. (B) Two-chamber view at the onset of treatment. (C) Four-chamber view after three months of treatment. (D) Two-chamber view after three months of treatment.](1349-7235-58-0239-g003){#g003}

![T2-weighted imaging showed the presence of edema indicating inflammation in the left ventricular myocardium. (A) Four-chamber view at the onset of treatment. (B) Two-chamber view at the onset of treatment. (C) Four-chamber view after three months of treatment. (D) Two-chamber view after three months of treatment.](1349-7235-58-0239-g004){#g004}

Three months later, cine imaging showed the improvement of the LV ejection fraction (47.9%; [Fig. 2E-H](#g002){ref-type="fig"}). The disappearance of pericardial effusion was observed on cine imaging, the LGE area in the LV myocardium was found to have decreased ([Fig. 3C and D](#g003){ref-type="fig"}), and the high-intensity area in the partial myocardium had normalized on TSE T2-weighted imaging ([Fig. 4C and D](#g004){ref-type="fig"})．

In this case, CMR was useful for the early diagnosis of Löffler endocarditis to prevent systemic embolism, including cerebral infarct and assess the curative effects of steroid and immunosuppressant therapy．

Discussion
==========

EGPA, formerly known as Churg-Strauss syndrome, is one of the rarest multisystemic vasculitis belonging to the small vessel anti-neutrophil cytoplasmic antibody-associated vasculitides. Once suspected, vasculitis involvement of the gut, kidney, and/or heart must be investigated because they have been proven to have a significant association with poorer progress ([@B2]). Approximately 15-56% of patients with EGPA show clinical cardiac manifestations ([@B3]). To detect cardiac abnormalities, diagnostic imaging (e.g., chest X-ray, ECG, and UCG) is initially performed. In particular, UCG provides adequate information about cardiac abnormalities, while CMR has been shown to be a superior noninvasive method for detecting myocardial involvement in patients with EGPA ([@B4], [@B5])．

In the present case, CMR imaging was performed to detect the cardiac involvement and showed extensive endocardial LGE of almost the entire left ventricle, which was compatible with Löffler endocarditis, as previously reported ([@B6], [@B7]). Although it was difficult to distinguish whether this was due to ischemic heart disease or Löffler endocarditis based on endocardial LGE, we could have diagnosed Löffler endocarditis based on the CMR results because coronary artery disease (CAD) was excluded from the coronary angiography results performed in the previous hospital. Löffler endocarditis is often associated with large thrombus formation, which may lead to systemic embolism. The initiation of anticoagulation therapy with heparin carries few risks, even without differentiating between CAD and Löffler endocarditis．

The greatest advantage of a diagnostic approach using CMR is the possibility of avoiding myocardial biopsy. We hesitated in performing CMR due to a cardiac rhythm abnormality and a worsening of the respiratory status. Fortunately, sinus rhythm was maintained in this case; thus, CMR was immediately performed after the patient's breathing status improved following steroid therapy. Cine and LGE imaging may be sufficient to make a diagnosis of Löffler endocarditis. In this case, T2-weighted imaging was the key method for investigating the presence of edema indicating inflammation in the LV myocardium. Cine imaging revealed pericardial effusion and diffuse hypokinesis of the LV wall motion. These findings showed that eosinophilic myocarditis was complicated. CMR is reported to be a useful tool for monitoring reversible and irreversible myocardial tissue injuries over the course of myocarditis ([@B7]). Comparing T2-weighted imaging with LGE imaging makes it easy to assess inflammation of the LV myocardium．

EGPA with Löffler endocarditis is frequently associated with a poor prognosis. Thus, cardiovascular problems should be evaluated and treatment should be started as early as possible. CMR may also be useful for assessing cardiovascular problems secondary to EGPA and for determining curative effects without myocardial biopsy．
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